A cloud?based, multi?modal, cognitive ophthalmic imaging platform for enhanced clinical trial design and personalized medicine in blinding eye disease
Age Related Macular Degeneration is the leading cause of irreversible blindness in Canada and the industrialized world, yet there are no treatments for most patients. Tracery Ophthalmics has developed an imaging method, “AMD Imaging” (AMDI) that has generated unprecedented pictures of the retina (film of the eye) that include both known and unknown “flavours” of disease (phenotype). These complex images will be compared against an individual’s genetic makeup (their genotype) and their concurrent illnesses, medications, and lifestyle history (their epigenetics). Tracery’s imaging will help identify patients that will benefit from TMi’s drug development program, and ultimately help doctors choose which treatment will work best. During this project, we will involve medical experts and their patients to generate and amass AMDI images, evaluating them over time and against other modalities. Cloud?based computing will be leveraged to integrate image?based and structured data, genomics and large data analytic to unite global users.